Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.40 |
| ▸ | TUBB | P07437 | 1/20 | 0.40 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.40 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.40 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.40 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.40 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.40 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.40 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.40 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.40 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.40 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.40 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9641851 | 0.98 | ABCB11 (0.97) | ABCB11MAPTHTTKDM4ETP53 | |
| SCHEMBL9642681 | 0.98 | ABCB11 (0.97) | ABCB11MAPTHTTKDM4ETP53 | |
| SCHEMBL9641850 | 0.91 | ABCB11 (0.83) | ABCB11MAPTHTTKDM4ETP53 | |
| SCHEMBL9627469 | 0.91 | ABCB11 (0.83) | ABCB11MAPTHTTKDM4ETP53 | |
| SCHEMBL9629374 | 0.91 | ABCB11 (0.83) | ABCB11MAPTHTTKDM4ETP53 | |
| SCHEMBL9642000 | 0.91 | ABCB11 (0.83) | ABCB11MAPTHTTKDM4ETP53 | |
| SCHEMBL9643348 | 0.90 | ABCB11 (0.81) | ABCB11MAPTHTTKDM4ETP53 | |
| SCHEMBL10781871 | 0.90 | ABCB11 (0.81) | ABCB11MAPTHTTKDM4ETP53 | |
| SCHEMBL9643774 | 0.90 | ABCB11 (0.81) | ABCB11MAPTHTTKDM4ETP53 | |
| SCHEMBL9641979 | 0.90 | ABCB11 (0.81) | ABCB11MAPTHTTKDM4ETP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 719 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250332143-A1 | COMPOSITION COMPRISING ALOX5 INHIBITOR FOR PREVENTING OR TREATING SARCOPENIA | PLUTO INC (KR) | 2025-10-30 | — | — | US | claimed |
| EP-4494639-A1 | COMPOSITION COMPRISING ALOX5 INHIBITOR FOR PREVENTING OR TREATING SARCOPENIA | Pluto Inc. (KR) | 2025-01-22 | — | — | EP | claimed |
| WO-2023177128-A1 | COMPOSITION COMPRISING ALOX5 INHIBITOR FOR PREVENTING OR TREATING SARCOPENIA | 주식회사 플루토 | 2023-09-21 | — | — | WO | claimed |
| US-20150320697-A1 | Methods For Bone Treatment By Modulating An Arachidonic Acid Metabolic or Signaling Pathway | ACCELALOX, INC. | 2015-11-12 | — | — | US | claimed |
| EP-1947942-B1 | METHODS FOR BONE TREATMENT BY MODULATING AN ARACHIDONIC ACID METABOLIC OR SIGNALING PATHWAY | ACCELALOX INC (US) | 2015-07-29 | — | — | EP | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-8980851-B2 | Methods for bone treatment by modulating an arachidonic acid metabolic or signaling pathway | ACCELALOX, INC. (US) | 2015-03-17 | — | — | US | claimed |
| WO-2014031586-A2 | METHODS FOR TREATING CARDIOVASCULAR DISEASES | TALLIKUT PHARMACEUTICALS, INC. (US) | 2014-02-27 | — | — | WO | claimed |
| US-8268352-B2 | Modified release composition for highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-18 | — | — | US | claimed |
| US-8263125-B2 | Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-11 | — | — | US | claimed |
| CN-1268887-A | Novel compounds for the treatment of psoriasis | GIORGIO ENDRICI (IT) | 2000-10-04 | — | — | CN | claimed |
| EP-0888127-A1 | COMBINATIONS HAVING IMMUNOSUPPRESSIVE EFFECTS, CONTAINING CYCLOOXYGENASE-2-INHIBITORS AND 5-LIPOXYGENASE INHIBITORS | G.D. SEARLE & CO. (US) | 1999-01-07 | — | — | EP | claimed |
| EP-0833622-A1 | COMPOSITIONS COMPRISING A CYCLOOXYGENASE-2 INHIBITOR AND A 5-LIPOXYGENASE INHIBITOR | G.D. SEARLE & CO. (US) | 1998-04-08 | — | — | EP | claimed |
| EP-0800815-A2 | Use of at least one lypoxygenase inhibitor and at least one cyclo-oxygenase inhibitor to alter hair growth | L'OREAL (FR) | 1997-10-15 | — | — | EP | claimed |
| WO-1997029776-A1 | COMBINATIONS HAVING IMMUNOSUPPRESSIVE EFFECTS, CONTAINING CYCLOOXYGENASE-2-INHIBITORS AND 5-LIPOXYGENASE INHIBITORS | G.D. SEARLE & CO. (US) | 1997-08-21 | — | — | WO | claimed |
| WO-1996041626-A1 | COMPOSITIONS COMPRISING A CYCLOOXYGENASE-2 INHIBITOR AND A 5-LIPOXYGENASE INHIBITOR | G.D. SEARLE & CO. (US) | 1996-12-27 | — | — | WO | claimed |
| EP-0648488-A1 | Method to alter hairgrowth and compositions therefor | L'OREAL (FR) | 1995-04-19 | — | — | EP | claimed |
| US-4933489-A | Process for the manufacture of 6-chloro-1,4-diacetoxy-2,3-dimethoxynaphthalene | WARNER-LAMBERT COMPANY (US) | 1990-06-12 | — | — | US | claimed |
| EP-0221474-B1 | PROCESS FOR THE MANUFACTURE OF 6-CHLORO-1,4-DIACETOXY-2,3-DIMETHOXYNAPHTHALENE | WARNER-LAMBERT COMPANY (US) | 1990-01-17 | — | — | EP | claimed |
| EP-0221474-A1 | Process for the manufacture of 6-chloro-1,4-diacetoxy-2,3-dimethoxynaphthalene | WARNER-LAMBERT COMPANY (US) | 1987-05-13 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250332143-A1 | COMPOSITION COMPRISING ALOX5 INHIBITOR FOR PREVENTING OR TREATING SARCOPENIA | MYOF, ALOX5, MYLK2 | ABCB11 4875/4885MAPT 3742/4885HTT 2822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.